Abstract
Background: No clinically significant changes in hematology/chemistry parameters were reported after clinical trials of dupilumab in adults with atopic dermatitis (AD). Here, we report laboratory outcomes in adolescent patients (aged ≥12 to <18 years) from an ongoing, long-term, OLE trial (LIBERTY AD PED-OLE; NCT02612454).
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have